| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9dc500810ecf90706ca7e3c69a374604
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fdaa64756184e715af6cb25ebc318917 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-785
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-02 |
| filingDate |
2013-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_042d33320fee141f7080574edb09700b |
| publicationDate |
2015-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8969302-B2 |
| titleOfInvention |
Low frequency glatiramer acetate therapy |
| abstract |
A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9702007-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018042415-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2630962-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4252849-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9617596-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE49251-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9155776-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9763993-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9155775-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2949335-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4252629-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11167003-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9402874-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019036363-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9625473-B2 |
| priorityDate |
2009-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |